

1 **Induction of Sertoli cells from human fibroblasts by NR5A1 and**
2 **GATA4**

3
4 **Jianlin Liang¹, Nan Wang¹, Jing He¹, Jian Du¹, Yahui Guo¹, Lin Li¹, Kehkooi Kee^{1,2*}**
5

6
7 ¹Center for Stem Cell Biology and Regenerative Medicine, Department of Basic Medical Sciences, School of
8 Medicine, Tsinghua University, Beijing, 100084, China.

9 ²Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing
10 100084, China.

11
12
13
14
15

*** Corresponding author: Kehkooi Kee, kkee@tsinghua.edu.cn**

16 **Abstract**

17 Sertoli cells are essential nurse cells in the testis that regulate the process of spermatogenesis and establish the
18 immune-privileged environment of the blood-testis-barrier (BTB). The induction of human Sertoli cells from
19 fibroblasts could provide cellular sources for fertility and transplantation treatments. Here, we report the *in vitro*
20 reprogramming of human fibroblasts to Sertoli cells and characterize these human induced Sertoli cells (hiSCs).
21 Initially, five transcriptional factors (NR5A1, GATA4, WT1, SOX9 and DMRT1) and a gene reporter carrying the
22 AMH promoter were utilized to obtain the hiSCs. We further reduce the number of reprogramming factors to two, i.e.,
23 NR5A1 and GATA4, and show that these hiSCs have transcriptome profiles that are similar to those of primary
24 human Sertoli cells. Consistent with the known cellular properties of Sertoli cells, hiSCs attract endothelial cells and
25 exhibit high number of lipid droplets in the cytoplasm. More importantly, hiSCs can sustain the viability of
26 spermatogonia cells harvested from mouse seminiferous tubules. In addition, hiSCs suppress the production of IL-2
27 and proliferation of human T lymphocytes. When hiSCs were cotransplanted with human embryonic kidney cells,
28 these xenotransplanted human cells survived longer in mice with normal immune systems. hiSCs also allow us to
29 determine a gene associated with Sertoli-only syndrome (SCO), *CX43*, is indeed important in regulating the
30 maturation of Sertoli cells.

31 **Introduction**

32 Sertoli cells are the first somatic cell type to differentiate in the testis and the only somatic cell type inside the
33 seminiferous tubules. Sertoli cells play a critical role in directing testis morphogenesis and the creation of an
34 immune-privileged microenvironment, which is required for male germ cell development. During early gonad
35 development, male somatic cells express the male sex-determining gene *SRY*, which directs the sex-specific vascular
36 development and seminiferous cord formation¹⁻³ via the initiation of a cascade of genes, including *SOX9*, *FGF9*,
37 *AMH* and *PGD2*^{4,5}. *NR5A1* (or *SF1*), *GATA4*, and *WT1* are major transcriptional factors that direct somatic cells to
38 become fetal Sertoli cells⁶. The expanding fetal Sertoli cells and another type of testicular somatic cell (i.e.,

39 peritubular cells) regulate the final organization and morphogenesis of the developing gonad into a testis^{7,8}.

40 Sertoli cells are the pivotal somatic cell regulators inside the seminiferous cord. Sertoli cells embed male germ cells

41 during all differentiating stages and provide immunological, nutritional and structural support for germ cell

42 development⁹. Sertoli cells secrete the growth factors and cytokines needed for proper spermatogenesis, including the

43 maintenance of spermatogonial stem cells, meiosis initiation of spermatocytes, and maturation of spermatozoa¹⁰.

44 Furthermore, Sertoli cells have the unique ability to modulate immunoreactions that protect the developing germ cells

45 from immunological attacks. The immune-privileged potential of Sertoli cells has been utilized in many allo- and

46 xeno-grafts to reduce the immune response in the field of cell transplantation¹¹⁻¹³. Preclinical studies have

47 transplanted Sertoli cells with various other cell types for the treatment of diabetes, neurodegenerative diseases,

48 Duchenne muscular dystrophy, skin allografts and other diseases¹⁴.

49 Recently, co-cultures of differentiated rodent primordial germ cells and neonatal testicular somatic cells have

50 successfully enabled meiosis completion and round spermatid formation *in vitro*¹⁵, highlighting the potential use of

51 testicular somatic cells in the field of reproductive medicine. Human pluripotent stem cells have been differentiated to

52 spermatid-like cells^{16,17}, but the co-culturing of stem cells with Sertoli cells could enhance the efficiencies of

53 obtaining functional male gametes. However, the procurement of human Sertoli cells is not feasible because of

54 biological and ethical constraints. The availability of donated Sertoli cells is limited, and expanding the limited

55 number of human Sertoli cells *in vitro* remains a challenge^{18,19}. Therefore, the generation of patient-specific Sertoli

56 cells from fibroblasts could alleviate these issues and fulfill the basic research and clinical demands.

57 Direct lineage reprogramming has been considered a promising strategy for obtaining functional cell types with lower

58 teratoma risks than directed differentiation of pluripotent stem cells^{20,21}. The induction of cell type conversion

59 between divergent lineages has been achieved using combinations of lineage-specific transcription factors²²⁻²⁵.

60 Fibroblasts are common cells in animal connective tissues that can be conveniently obtained from patients. Therefore,

61 fibroblasts are often used as initiating cells in many lineage reprogramming experiments. The direct reprogramming of

52 Sertoli cells from fibroblasts has been demonstrated in mouse by overexpressing five defined transcriptional factors ²⁶,
53 but the direct lineage conversion of human Sertoli cells from fibroblasts has not been described. Here, we report the
54 efficient induction of human Sertoli cells (hiSCs) from both human pulmonary fibroblasts (HPF) and fibroblasts
55 derived from human embryonic stem cells (hESCs) by overexpressing GATA4 and NR5A1. These hiSCs exhibit an
56 epithelial morphology, lipid droplet accumulation, and transcriptomes similar to those of primary Sertoli cells; sustain
57 the growth of mouse spermatogonia cells; and perform immune-privileged function during transplantation
58 experiments.

59 Connexin 43 (CX43) is a predominant gap junction protein expressed in BTBs that affects the maturation of Sertoli
60 cells and spermatogenesis ²⁷⁻³⁰. The deletion of CX43 in Sertoli cells, but not germ cells, causes infertility in mice ^{27,31}.
61 The absence of CX43 expression in human Sertoli cells is associated with Sertoli cell-only syndrome (SCO) and
62 impaired spermatogenesis in male patients ^{32,33}, but whether the deletion of CX43 directly affects the characteristics of
63 human Sertoli cells has not been demonstrated. Utilizing our *in vitro* hiSC model, we demonstrate that the deletion of
64 CX43 affects the transcriptome profile and maturation of hiSCs.

75 **Results**

76 **Testing the reprogramming capability of five putative transcriptional factors**

77 Based on the reprogramming capability of the transcriptional factors reported in a mouse study ²⁶, we first tested the
78 reprogramming capabilities of the human homologs of the five transcriptional factors (5TFs: NR5A1, GATA4, WT1,
79 SOX9 and DMRT1) to convert human fibroblasts to hiSCs. All five human homologs were correctly cloned into
80 lentiviral vectors and expressed at high levels as verified by immunofluorescent staining of HPFs (Fig. 1a). After the
81 lentiviral transduction with all five factors and culturing in selective medium for 5 days, many HPFs started to
82 transform from the typical elongated morphology of fibroblasts into the squamous morphology that typically appears
83 in epithelial cells (Supplementary Fig. 1a). The analysis of the transcriptional expression showed that genes enriched
84 in Sertoli cells, such as *AR*, *KRT18*, *CLU*, *PTGDS*, *SCF*, *BMP4* and *INHA*, exhibited increased expression in this

35 mixed population of transformed HPFs (Supplementary Fig. 1b). To determine whether these 5TFs were able to
36 reprogram other fibroblast sources, we derived human fibroblast-like cells from hESC line H1 (dH1) and
37 reprogrammed these cells as described for the HPFs. The dH1 morphology resembled that of fibroblasts, and no
38 detectable expression of pluripotent markers was observed, but the expression of many markers of fibroblasts was
39 observed (Supplementary Fig. 2a,b,c). After the transduction of the 5TFs, dH1 underwent a fibroblast to epithelial
40 transformation similar to that observed in the HPFs (Supplementary Fig. 2d), suggesting that the 5TFs can transform
41 both types of fibroblasts into epithelial-like cells and increase the expression of Sertoli cell markers.

42 To isolate and enrich the hiSCs in the mixed population of reprogrammed fibroblasts, we constructed a gene reporter
43 system utilizing the 1.6 kb promoter region of *AMH*, which is a gene specifically expressed in Sertoli cells³⁴,
44 connected to EGFP (Fig. 1c). When the lentivector carrying the reporter, AMH:EGFP, was stably integrated into HPFs
45 and dH1, none of the cells would express EGFP without transcriptional induction. After the transduction and selection
46 of the fibroblasts, some reprogrammed cells were expected to express EGFP to allow us to isolate them by
47 fluorescence-activated cell sorting (FACS). We found that both HPF and dH1 reproducibly yielded a clear
48 AMH:EGFP-positive population after 10 days of transduction with the 5TFs (Fig. 1d). Intriguingly, the AMH:EGFP+
49 population in the dH1 group (~15%) was much higher than that in the HPF group (~6%), indicating that the
50 conversion of the dH1 cells was more efficient. The AMH:EGFP+ cells were isolated by FACS and adhered to culture
51 dishes and exhibited an epithelial morphology (Fig. 1e). We verified that the endogenous AMH expression was
52 activated because the expression level of the *AMH* gene was significantly upregulated in the AMH:EGFP+ cell
53 population compared to that in the control dH1 cells (CTRL) and AMH:EGFP- cells (Fig. 1f). Moreover, an epithelial
54 marker expressed in Sertoli cells, i.e., KRT18, was used to validate the transformation of the fibroblasts to Sertoli cells.
55 The cytoskeleton pattern of KRT18 expression was observed in the AMH:EGFP+ cells but not the control dH1 cells
56 (Fig. 1g).

47 **Whole-genome transcriptional profiling of hiSCs resembling adult Sertoli cells**

38 To determine whether hiSCs reprogrammed with the 5TFs (5F-hiSCs) are similar to human Sertoli cells, we compared
39 the transcriptomes of the AMH:EGFP+ 5F-hiSCs, dH1 cells infected with p2k7 empty virus (dH1-2K7) as negative
40 controls, and primary adult Sertoli cells (aSCs) from human biopsy samples. We focused our analysis on the
41 differentially expressed genes (DEGs, > 2-fold change, p -value < 0.05) between 5F-hiSCs and dH1-2K7 and between
42 aSCs and dH1-2K7. In total, 7533 genes were differentially expressed between 5F-hiSCs and dH1-2K7, including
43 4528 upregulated genes and 3005 down-regulated genes (Fig. 2a,b). Additionally, 5377 genes were differentially
44 expressed between aSCs and dH1-2K7, including 3343 upregulated genes and 2034 down-regulated genes (Fig. 2a, b).
45 The Venn analysis showed that 3626 genes were shared among the DEGs in both hiSCs and aSCs, accounting for
46 approximately 67% of the DEGs in aSCs. Among this shared group of DEGs (CO-DEGs), 1973 genes were
47 upregulated, while 1314 genes were down-regulated in both the hiSCs and aSCs (Fig. 2c), indicating that the trends in
48 transcriptional expression between the hiSCs and aSCs were the same in these genes. The cluster analysis of dH1-2K7,
49 hiSCs and aSCs also showed that the CO-DEGs had a similar expression pattern between the hiSCs and aSCs, and
50 consistency was observed between duplicate samples (Fig. 2d). The Gene Ontology (GO) analysis of the CO-DEGs
51 showed that among the 1973 upregulated genes, many genes were involved in the regulation of cell communication,
52 regulation of immune response processes, response to hormones, and lipid metabolic process, whereas among the
53 1314 down-regulated genes, many genes were involved in the mitotic cell cycle and microtubule-based processes (Fig.
54 2e). These changes in gene expression indicated that the hiSCs acquired unique cellular characteristics that were
55 distinct from the original fibroblasts. To further confirm that the AMH:EGFP+ 5F-hiSCs have the signature of Sertoli
56 cells, we examined the expression of several Sertoli cell markers, including *CLU*, *NCAM2*, *DHH*, *ERBB4*, *INHB*,
57 *INHA*, *SHBG*, *GATA6*, *CDKN1B*, *TGF α* and *LMMA3*, by quantitative PCR (qPCR). Compared to the control cells, all
58 Sertoli cell markers were highly enriched in the AMH:EGFP+ 5F-hiSCs (Fig. 2f). Taken together, the transcriptional
59 profile of the AMH:EGFP+ 5F-hiSCs resembled that of the aSCs, and many Sertoli cell markers were expressed.

30 **NR5A1 and GATA4 are sufficient to reprogram fibroblasts to hiSCs as 5F-hiSCs**

31 Although the 5TFs yielded the AMH:EGFP⁺ hiSCs, the combination of all 5TFs may not be necessary to reprogram
32 fibroblasts to hiSCs. Therefore, we used fewer transcription factors to generate hiSCs and compared the percentage of
33 AMH:EGFP⁺ cells in all 31 combinations of NR5A1, GATA4, SOX9, WT1 and DMRT1 (Table S2). The FACS
34 results indicated that 16 combinations of transcriptional factors yielded varying levels of AMH:EGFP⁺ cells after 10
35 days of reprogramming (Fig. 3a). NR5A1 was the only common factor found in all 16 combinations in AMH:EGFP⁺
36 cells. This transcriptional factor alone generated approximately 3.79% of AMH:EGFP⁺ cells, and the combination of
37 all 5TFs produced the highest percentage of AMH:EGFP⁺ cells. Surprisingly, the combinations with NR5A1 and
38 GATA4 generated as many AMH:EGFP⁺ cells as all 5TF combined. Moreover, all combinations containing NR5A1
39 and GATA4 resulted in a similar level higher than the combinations with NR5A1 (Fig. 3b). The AMH:EGFP⁺ cells
40 generated by 2TFs and 5TFs showed similar morphologies, including a large cell body with an epithelial morphology,
41 and expressed KRT18 (Fig. 1g,3c).

42 Then, we analyzed and compared the transcriptome of the 2F-hiSCs and with the transcriptome of the aSCs and
43 5F-hiSCs. We identified the common DEGs among the dH1/aSCs, dH1/5F-hiSCs (dH1), dH1/2F-hiSCs (dH1) and
44 dH1/5F-hiSCs (HPF) and performed hierarchical clustering using their FPKM values. The analysis revealed that the
45 transcriptome profiles of the 2F-hiSCs were more similar to the profiles of the 5F-hiSCs and adult Sertoli cells (aSCs)
46 than to the dH1 and HPF profiles (data not shown). To identify the putative signature genes similar among the
47 2F-hiSCs, 5F-hiSCs and aSCs, we generated a heat map of the 1638 CO-DEGs and carried out gene correlation
48 clustering. Notably, the differentially expressed genes were grouped into three groups of 512, 689 and 437 genes. The
49 Gene Ontology analysis showed that many of the 512 highly expressed genes mostly shared by the 2F-hiSCs,
50 5F-hiSCs and aSCs were involved in reproductive structure development, immune effector processes and response to
51 hormones. These genes, including *KRT18*, *PTGDS* and *SOX9*, are used as markers of Sertoli cells or are highly
52 expressed in Sertoli cells^{26,35}. We further compared the expression of 59 genes that are highly expressed in Sertoli
53 cells³⁶⁻³⁸ among the 2F-hiSCs, 5F-hiSCs and aSCs. All three groups exhibited similar expression of many markers that

54 are expressed in more mature Sertoli cells, including *CDKN1B* (or *p27^{kip1}*) and *CLU*³⁹. However, some markers in the
55 aSCs, including *NCAM2*, *INHA* and *KRT18*^{39,40}, were expressed at lower levels (Supplementary Fig. 3) than those in
56 the other two hiSCs. The Sertoli cell marker expression was very similar between the 2F-hiSCs and 5F-hiSCs.
57 Therefore, we focused on the 2F-hiSCs for the subsequent more thorough characterization.

58 **2F-hiSCs attract human endothelial cells and accumulate lipid droplets**

59 Sertoli cells mediate the migration of endothelial cells to seminiferous tubules during testicular cord formation^{3,41}. We
60 investigated whether the hiSCs attracted human umbilical vein endothelial cells (HUVECs). The migration assay
61 showed that compared to ~40 cells under control conditions, the number of HUVECs that were attracted and passed
62 through the membrane was ~80 cells per unit after 20 hours of induction in conditioned media. These results indicate
63 that significantly more endothelial cells were attracted by the conditioned medium collected from the 2F-hiSCs than
64 by that collected from the dH1-2K7 cells (Fig. 4a,b).

65 Another unique feature of Sertoli cells in humans and other mammalian species is the accumulation of lipid droplets in
66 the cytoplasm^{42,43}. The Gene Ontology analysis showed that genes that participate in lipid metabolism processes were
67 upregulated in the 2F-hiSCs, 5F-hiSCs and aSCs (Fig. 3d), supporting the presence of high numbers of lipid droplets
68 in the hiSCs. We used BODIPY to stain and count the number of cells with high numbers of lipid droplets to
69 determine whether lipid droplets appeared in the 2F-hiSCs. The average percentage of cells that exhibited strong
70 BODIPY positivity was approximately 15% in the control cells and approximately 40% in the 2F-hiSCs. Therefore,
71 the percentage of cells containing high quantities of lipid droplets was approximately 2.7-fold higher in the 2F-hiSCs
72 group than that in the dH1-2K7 group (Fig. 4c, d)

73 **2F-hiSCs sustain *in vitro* culturing of mouse spermatogonia cells**

74 Mouse spermatogonia cells were isolated from seminiferous tubules of 6 dpp mice and co-cultured with dH1 or
75 2F-hiSCs to examine whether 2F-hiSCs sustain the growth of male germ cells (Fig. 5a, Supplementary Fig. 4). More
76 mouse germ cells attached and survived on the 2F-hiSCs than dH1 cells after a 12-hour culture (Fig. 5b). The

77 morphology of the round cells attached to the hiSCs appeared alive and resembled spermatogonia cells. The cells
78 attached to dH1 appeared apoptotic and degenerated. The co-cultured samples were fixed and immunostained 48
79 hours after plating to further confirm that the 2F-hiSCs formed solid attachments with the spermatogonia cells. The
80 immunostaining of the germ cell-specific marker DAZL (to identify mouse spermatogonia cells) and human-nuclear
81 specific marker NuMA (to identify hiSCs and dH1) indicated that significantly more DAZL-positive spermatogonia
82 cells attached to the hiSCs, but almost no DAZL-positive cells attached to the dH1 cells despite the similar numbers of
83 plated hiSCs and dH1 cells (Fig. 5c,d). Sertoli cells directly contact male germ cells in seminiferous tubules *in vivo*,
84 and we hypothesized that the hiSCs would directly contact the spermatogonia cells. We immunostained the
85 co-cultured cells with DAZL and KRT18 and found that many DAZL-positive cells localized to areas occupied by
86 hiSCs, typically at the edge of the cell bodies (Fig. 5e).

37 **2F-hiSCs suppress T cell proliferation, IL-2 production and protect transplanted human cells**

38 A specialized property of Sertoli cells is their functional role in creating an immune-privileged environment in
39 seminiferous tubules to protect germ cells from immunological attacks. Previous studies have shown this unique
40 function, which has been exploited in therapeutic transplantation for the protection of many other cell types¹¹. We first
41 investigated whether the medium from the 2F-hiSCs cells exhibited any suppressive effect on the proliferation of
42 Jurkat E6 cells (human T lymphocytes) to examine whether the 2F-hiSCs could suppress the immunoreaction of
43 immunological cells. The suppressive effect was evaluated using an assay commonly used to determine the active
44 metabolism of a proliferating cell, i.e., WST-1⁴⁴ (Fig. 6a). The Jurkat E6 cells were treated with various concentrations
45 of 2F-hiSCs-conditioned media and exhibited a significant dose-responsive decrease in cell proliferation compared to
46 that in cells treated with dH1-2K7-conditioned media (Fig. 6b). The proliferation level was ~35% lower in the Jurkat
47 lymphocytes exposed to the highest concentration of the 2F-hiSC-conditioned medium. We collected the Jurkat cells
48 and analyzed the protein levels of interleukin-2 (IL-2), which plays an essential role in the immune system. The
49 ELISA indicated that the IL-2 levels were significantly lower in the cells cultured with the 2F-hiSCs-conditioned

30 media than those in the cells cultured with the dH1-2K7-conditioned media (Fig. 6c). 21 gene previously known to
31 participate in immunosuppression of Sertoli cells^{12,45} or categorized as immune effector gene by gene ontology were
32 activated after reprogramming of dH1 (Fig. 6d), further confirmed that hiSCs acquired immunosuppressive function.
33 Approximately 1.3×10^6 human 293FT cells stably integrated with a luciferase-expressing vector were co-transplanted
34 with 2.5×10^5 dH1-2K7 or 2F-hiSCs cells into mice with normal immune systems via hypodermic injection to
35 determine whether the 2F-hiSCs could protect xenotransplanted cells. The transplantation experiment was performed
36 to investigate the immunosuppressive effects at different locations (foreleg, hindleg, left and right sides of the animals
37 as indicated on the figures) in two different animals, and the transplanted sites were monitored for up to 10 days.
38 D-luciferin was injected into the animals to follow the surviving transplanted 293FT cells, and the signal was
39 monitored using live imaging 15 minutes post-injection beginning 3 days after transplantation. The transplanted
40 293FT cells gradually diminished in the immunocompetent mouse from day 3 to day 10 (mouse #1, #2) as indicated
41 by the reduced luciferase activity at the transplanted sites (Fig. 6e, Supplementary Fig. 5). All 293FT cells
42 co-transplanted with hiSCs exhibited higher luciferase activity, which ranged from 1.7- to 3.9-fold, 3 days after
43 transplantation. Three of the four groups of transplanted cells survived until day 10, and two of the three groups of
44 293FT cells with hiSCs survived at least 10 days after transplantation with strong luciferase activity. In contrast, their
45 counterpart control cells exhibited less than 40-fold or no detectable luciferase activity (mouse #1 foreleg group and
46 mouse #2 hindleg group).

17 **CX43 deletion disrupts gap junctions and alters the expression profile of hiSCs**

18 We investigated whether the deletion of the gap junction protein CX43 could affect hiSCs formation and determined
19 whether hiSCs exhibit the same genetic requirements for development as Sertoli cells *in vivo*. We created a
20 homozygous deletion of *CX43* hESC line, derived fibroblasts from this line and compared the reprogramming
21 efficiency of the hiSCs (Fig. 7a). We successfully generated three targeted mutations at *CX43*, i.e., one single allele
22 mutation (#6) and two double allele mutations (#21 & #26) at Exon 2 of the *CX43* gene, using a CRISPR-CAS9 gene

23 editing system (Fig. 7b). The protein expression was completely disrupted in the CX43^{-/-} (#21) and CX43^{-/-} (#26) cell
24 lines, but the heterozygous protein level remained similar to the wild-type CX43 level based on the Western blot
25 analyses (Supplementary Fig. 6a). The immunostaining of CX43 (Fig. 7c) and photo bleaching assay (Fig. 7d,e) of
26 ES-derived fibroblasts (dH1) both showed that the expression of CX43 and gap junctions between neighboring cells
27 were disrupted because there was no detectable CX43 staining or diffusing fluorescent dye recovered after photo
28 bleaching in the CX43^{-/-} (#26) cell line.

29 We compared the reprogramming efficiency of the 2F-hiSCs between the wild-type dH1 and CX43KO (CX43^{-/-} (#26))
30 cell lines. The time course experiments showed that the percentage of AMH:EGFP⁺ in the WT hiSCs peaked at ~13.8%
31 on day 15 and decreased to 3.3% on day 25 (Fig. 7f, g; Supplementary Fig. 6b). Remarkably, the percentage of
32 AMH:EGFP⁺ in the CX43^{-/-} (#26) cell line was 23.9% on day 15 and decreased to 18.5% on day 25, but the
33 overexpression of CX43 in the deletion cell line revealed a much lower percentage of AMH:EGFP⁺ from days 4 to 25.
34 Therefore, the expression level of CX43 in the cells was indirectly proportional to the percentage of AMH:EGFP⁺
35 cells. This result is consistent with the higher AMH expression in CX43 knockout mice reported in a previous study³⁰
36 and suggests that the effect of the CX43 deletion leads to the dedifferentiation of Sertoli cells to a less mature state.

37 The high percentage of AMH:EGFP⁺ cells in the CX43KO cells may be due to their more immature status than that of
38 WT AMH:EGFP⁺ hiSCs. Therefore, we compared the transcriptional profiles of these two populations to examine
39 whether CX43KO affected gene expression or any cellular processes. The volcano analysis revealed that 2736 genes
40 were differentially expressed (*p*-value less than 0.01) between the CX43KO 2F-hiSCs and WT 2F-hiSCs
41 (Supplementary Fig. 7a). We found 754 genes with a difference in the transcript level greater than two-fold; 512 genes
42 were down-regulated and 242 genes were upregulated in the CX43KO 2F-hiSCs compared to those in the WT
43 2F-hiSCs (Supplementary Fig. 7b). We further analyzed the 755 genes using a heat map and GO analysis to identify
44 specific genes or processes affected by CX43KO. The genes were classified into 8 gene sets according to the
45 expression patterns among the WT dH1, WT 2F-hiSCs, CX43KO dH1 and CX43KO 2F-hiSCs (Fig. 7h,

46 Supplementary Fig. 7c). The genes in Groups 1 and 4 exhibited lower expression levels in the WT 2F-hiSCs and
47 CX43 2F-hiSCs than in the other two groups of control cells, suggesting that these genes were affected by the
48 reprogramming process. The genes in Groups 5 and 6 exhibited similar patterns between the WT cells and CX43KO
49 cells, suggesting that these two groups were affected by CX43KO. In contrast, the expression profiles of the genes in
50 Groups 2, 3, 7, and 8 in the WT and CX43KO hiSCs differed from those in their counterpart controls and between the
51 WT and CX43KO hiSCs. These genes may reflect the cellular maturation status of these two reprogrammed cell
52 populations. The GO analysis of enriched terms in these 4 groups revealed that Group 2 was enriched with genes
53 involved in catabolic processes, including nucleobase-containing compound catabolic process, and Group 3 contained
54 genes involved in steroid metabolic or lipid biosynthetic processes. Group 7 included many genes that participated in
55 the cytoskeleton, and Group 8 contained genes related to gamete generation.

56 Ten marker genes previously reported to be more highly expressed in mature or immature Sertoli cells^{35,39} were
57 chosen for the expression level comparisons between WT and CX43KO hiSCs. The CX43KO hiSCs exhibited a
58 higher expression of some immature markers and lower expression of mature markers, suggesting that the CX43KO
59 cells were more immature than the WT hiSCs.

50

51 **Discussion**

52 This study reported that human fibroblasts can be reprogrammed to Sertoli-like cells using 5TFs (NR5A1,
53 GATA4, WT1, DMRT1 and SOX9) or 2TFs (NR5A1 and GATA4). Fibroblasts from two sources, i.e., human
54 pulmonary fibroblasts and fibroblasts derived from human embryonic stem cells, were reprogrammed to Sertoli-like
55 cells and exhibited transcriptomes similar to those of primary adult Sertoli cells. The present study generated a Sertoli
56 cell-specific gene reporter, i.e., AMH:EGFP, to enhance the efficiency of isolating a relatively pure population of
57 hiSCs from a mixed population of cells at different reprogramming stages (Fig. 1, 2). AMH has been used in many
58 conditioned knockout studies to specify the expression of Cre recombinase in Sertoli cells⁴⁶. We cloned the human

59 promoter of *AMH* and fused it to EGFP and showed that the cell population expressing EGFP appeared only after
70 reprogramming, and these cells expressed many Sertoli cell marker genes. The success of reprogramming human
71 fibroblasts with the same factors used in a previous mouse study²⁶ confirms that the reprogramming capability of
72 these 5TFs is conserved between humans and mice.

73 Another achievement of this study was the reduction in the reprogramming factors from 5TFs to 2TFs. NR5A1,
74 which is often called SF1, was the most essential of the five factors because almost no AMH:EGFP+ cells appeared in
75 the reprogramming experiments without NR5A1, even if GATA4, WT1, DMRT1 and SOX9 were overexpressed (Fig.
76 3a, b). Notably, only the addition of GATA4, but not the addition of the three other TFs, to the reprogramming
77 combination increased the percentage of AMH:EGFP+ cells. Several TFs, including NR5A1 and GATA4, are key
78 regulators establishing the mouse Sertoli cell identity⁶. Therefore, unsurprisingly, NR5A1 and GATA4 were sufficient
79 to reprogram human fibroblasts to Sertoli-like cells. WT1 and SOX9 are also determining factors in mouse Sertoli
80 cells, but their reprogramming abilities were lower than those of NR5A1 and GATA5. SOX9 interacts with NR5A1 to
81 trigger the specific onset of AMH expression⁴⁷, but SOX9 overexpression in our reprogramming experiments only
82 slightly increased the percentage of AMH:EGFP+ cells in a few combinations of TFs (Fig. 3a, b).

83 The cellular characterizations of the 2F-hiSCs showed that these cells carried many known properties of Sertoli
84 cells. Lipid metabolism in Sertoli cells is important for providing nutritional and energy supplies to germ cells⁴².
85 Previous studies have shown that the high metabolic activity requirements for lipid and steroid synthesis are
86 associated with the differentiated status of Sertoli cells^{48,49}. Notably, the hiSCs in the present study exhibited a high
87 expression of lipid and steroid related genes (Fig. 3d), and the WT hiSCs exhibited a higher expression than the
88 CX43KO hiSCs (Fig. 7h). These results suggest that the hiSCs were similar to differentiated Sertoli cells *in vivo*. The
89 lipid droplet staining assays clearly showed the presence of high numbers of lipid droplets in the hiSCs but not the
90 fibroblasts used for reprogramming (Fig. 4b).

91 Sustaining the viability and differentiation of spermatogonia cells is the most essential function of Sertoli cells.

32 We examined the ability of hiSCs to sustain mouse spermatogonia cells because of the inaccessible procurement of
33 human spermatogonia cells from hospitals. Previous studies performing xenotransplantation experiments transplanting
34 primate spermatogonia stem cells into mouse testis demonstrated that primate germ cells colonized in the seminiferous
35 tubules of the recipient mice, but the primate germ cells did not differentiate because of the evolutionary differences
36 between these species⁵⁰. The isolated mouse spermatogonia cells in our study attached and survived on the hiSCs, but
37 no differentiated spermatocytes were detected (Fig. 5b, c; data not shown). These results suggest that the
38 reprogrammed Sertoli cells were only capable of providing a niche for the survival of male germ cells *in vitro*. Recent
39 studies have reported *in vitro* derivations of immature human gametes from hESCs^{16,17,51}. The male and female
40 gametes in these studies were immature likely due to the absence of fully competent somatic cells in the
41 differentiating culture. Therefore, adding induced Sertoli cells or granulosa cells to *in vitro* differentiating cultures
42 may be a key step in obtaining fully functional gametes *in vitro*.

33 Another prominent role of Sertoli cells is the creation of an immune-privileged environment to protect germ cells
34 from immune attacks of lymphocytes. Many studies have documented that Sertoli cells secrete factors that suppress
35 the proliferation of T cells, B cells and NK cells^{14,45}, including the suppression of IL-2 from T cells⁵². Our results
36 indicate that culture media incubated with hiSCs suppress the proliferation of Jurkat cells (the immortalized cell line
37 of human T lymphocytes) and reduce IL-2 production in Jurkat cells treated with hiSC-conditioned media (Fig. 6b,c).
38 Many genes previously known to participate in immune effector processes were upregulated in the hiSCs compared to
39 those in fibroblasts (Fig. 6d), suggesting that hiSCs modulate immune suppression via multiple immunological
40 pathways. Notably, all 293FT cells co-transplanted with hiSCs into two different immunocompetent mice survived
41 longer than their counterpart control cells co-transplanted with fibroblasts (Fig. 6e and Supplementary Fig. 5). These
42 results suggest that the hiSCs protected the xenotransplanted 293FT cells from host immune cells. Previous studies
43 have reported that Sertoli cells protect many cell types in allogenic and xenogenic transplantation, and several studies
44 used immunosuppressive drugs or immune-deficient mice in long-term follow-up experiments^{11,12}. One study

15 xenotransplanted porcine Sertoli cells with rat islet cells into the kidney capsule of immunocompetent rats⁵³. The islet
16 allografts survived 8 to 9 days when 1.5×10^6 porcine Sertoli cells were co-transplanted. In our experiments, 2.5×10^5
17 hiSCs were co-transplanted with 293FT cells and survived at least 10 days in two mice. Therefore, our
18 xenotransplanted 293FT cells survived a similar or longer duration with lower numbers of reprogrammed human
19 Sertoli cells in immunocompetent mice. Long-term transplantations of hiSCs with clinically relevant cell types,
20 including pancreatic islets and skin grafts, should be investigated for potential clinical applications, such as the
21 treatment of diabetes and skin burns. Our hiSCs have the advantage of being of human origin, which alleviates the
22 issue of xenotransplantation and potential of animal virus infection.

23 Reprogrammed Sertoli cells may be used as a model for examining the cellular and genetic mechanisms of
24 human Sertoli cell biology. A previous study reported an association between Sertoli-only syndrome (SCO) and the
25 lower mRNA expression of CX43³² and suggested that the absence of CX43 rendered the Sertoli cells more immature.
26 However, the precise mechanism by which the absence of CX43 causes infertility is unclear. Our studies revealed that
27 multiple pathways, including lipid metabolism and nucleobase catabolism, were more highly expressed in the WT
28 than in the CX43KO hiSCs, indicating that the absence of CX43 disrupts these molecular pathways in Sertoli cells.
29 The expression of several markers of immature Sertoli cells was higher and the expression of markers of mature
30 Sertoli cells was lower in CX43KO than in the WT hiSCs. Taken together, our results suggest that the deletion of
31 CX43 disrupts multiple molecular pathways and delays the maturation of Sertoli cells.

32

33 **References**

- 34 1 Koopman, P., Münsterberg, A., Capel, B., Vivian, N. & Lovellbadge, R. Expression of a candidate sex-determining gene
35 during mouse testis differentiation. *Nature* **348**, 450-452 (1990).
- 36 2 Bott, R. C., Mcfee, R. M., Clopton, D. T., Toombs, C. & Cupp, A. S. Vascular endothelial growth factor and kinase
37 domain region receptor are involved in both seminiferous cord formation and vascular development during testis
38 morphogenesis in the rat. *Biology of reproduction* **75**, 56 (2006).
- 39 3 Brennan, J., Tilmann, C. & Capel, B. Pdgfr-alpha mediates testis cord organization and fetal Leydig cell development in
40 the XY gonad. *Genes & Development* **17**, 800-810 (2003).
- 41 4 Barrionuevo, F. *et al.* Testis cord differentiation after the sex determination stage is independent of Sox9 but fails in the
42 combined absence of Sox9 and Sox8. *Developmental Biology* **327**, 301-312, doi:10.1016/j.ydbio.2008.12.011 (2009).

- 43 5 Moniot, B. *et al.* The PGD2 pathway, independently of FGF9, amplifies SOX9 activity in Sertoli cells during male sexual
44 differentiation. *Development* **136**, 1813-1821, doi:10.1242/dev.032631 (2009).
- 45 6 Yao, H. H., Ungewitter, E., Franco, H. & Capel, B. in *Sertoli Cell Biology, Second Edition* (ed Michael D. Griswold)
46 Ch. Establishment of fetal Sertoli cells and their role in testis morphogenesis, (Elsevier, 2015).
- 47 7 Griswold, M. D. The central role of Sertoli cells in spermatogenesis. *Semin Cell Dev Biol* **9**, 411-416,
48 doi:10.1006/scdb.1998.0203 (1998).
- 49 8 McLaren, A. Germ and somatic cell lineages in the developing gonad. *Molecular and cellular endocrinology* **169** (2000).
- 50 9 Oatley, J. M. & Brinster, R. L. The germline stem cell niche unit in mammalian testes. *Physiological Reviews* **92**,
51 577-595 (2012).
- 52 10 Hai, Y. *et al.* The roles and regulation of Sertoli cells in fate determinations of spermatogonial stem cells and
53 spermatogenesis. *Seminars in Cell & Developmental Biology* **29**, 66-75,
54 doi:<http://dx.doi.org/10.1016/j.semcdb.2014.04.007> (2014).
- 55 11 Kaur, G., Thompson, L. A. & Dufour, J. M. Therapeutic potential of immune privileged Sertoli cells. **12**, 105-117
56 (2015).
- 57 12 Mital, P., Kaur, G. & Dufour, J. M. Immunoprotective sertoli cells: making allogeneic and xenogeneic transplantation
58 feasible. *Reproduction* **139**, 495 (2010).
- 59 13 Valdés González, R. A. *et al.* Xenotransplantation of porcine neonatal islets of Langerhans and Sertoli cells: a 4-year study.
60 *European Journal of Endocrinology* **153**, 419-427 (2005).
- 61 14 Luca, G. *et al.* Sertoli cells for cell transplantation: pre-clinical studies and future perspectives. *Andrology*,
62 doi:10.1111/andr.12484 (2018).
- 63 15 Zhou, Q. *et al.* Complete Meiosis from Embryonic Stem Cell-Derived Germ Cells In Vitro. *Cell Stem Cell* (2016).
- 64 16 Kee, K., Angeles, V. T., Flores, M., Nguyen, H. N. & Reijo Pera, R. A. Human DAZL, DAZ and BOULE genes modulate
65 primordial germ-cell and haploid gamete formation. *Nature* **462**, 222-225, doi:10.1038/nature08562 (2009).
- 66 17 Easley, C. A. t. *et al.* Direct differentiation of human pluripotent stem cells into haploid spermatogenic cells. *Cell reports*
67 **2**, 440-446, doi:10.1016/j.celrep.2012.07.015 (2012).
- 68 18 Kulibin, A. Y. & Malolina, E. A. Only a small population of adult Sertoli cells actively proliferates in culture.
69 *Reproduction* **152**, 271-281, doi:10.1530/rep-16-0013 (2016).
- 70 19 Chaudhary, J., Sadler-Riggelman, I., Ague, J. M. & Skinner, M. K. The helix-loop-helix inhibitor of differentiation (ID)
71 proteins induce post-mitotic terminally differentiated sertoli cells to re-enter the cell cycle and proliferate. *Biology of*
72 *Reproduction* **72**, 1205-1217, doi:10.1095/biolreprod.104.035717 (2005).
- 73 20 Cherry, A. B. & Daley, G. Q. Reprogramming cellular identity for regenerative medicine. *Cell* **148**, 1110-1122 (2012).
- 74 21 Xu, J., Du, Y. & Deng, H. Direct Lineage Reprogramming: Strategies, Mechanisms, and Applications. *Cell Stem Cell* **16**,
75 119 (2015).
- 76 22 Yamanaka, S. & Blau, H. M. Nuclear reprogramming to a pluripotent state by three approaches. *Nature* **465**, 704 (2010).
- 77 23 Nam, Y. J. *et al.* Reprogramming of human fibroblasts toward a cardiac fate. *Proceedings of the National Academy of*
78 *Sciences* **110**, 5588 (2013).
- 79 24 Huang, P. *et al.* Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. *Cell Stem Cell* **14**,
80 370-384, doi:10.1016/j.stem.2014.01.003 (2014).
- 81 25 Hendry, C. E. *et al.* Direct transcriptional reprogramming of adult cells to embryonic nephron progenitors. *Journal of the*
82 *American Society of Nephrology* **24**, 1424-1434 (2013).
- 83 26 Buganim, Y. *et al.* Direct Reprogramming of Fibroblasts into Embryonic Sertoli-like Cells by Defined Factors. *Cell Stem*
84 *Cell* **11**, 373-386, doi:10.1016/j.stem.2012.07.019 (2012).
- 85 27 Brehm, R. *et al.* A sertoli cell-specific knockout of connexin43 prevents initiation of spermatogenesis. *Am J Pathol* **171**,
86 19-31, doi:10.2353/ajpath.2007.061171 (2007).
- 87 28 Sridharan, S. *et al.* Proliferation of adult Sertoli cells following conditioned knockout of the gap junctional protein GJA1
88 (Connexin 43) in mice. *Biology of Reproduction* **76**, 804-812, doi:10.1095/biolreprod.106.059212 (2007).
- 89 29 Gerber, J., Heinrich, J. & Brehm, R. Blood-testis barrier and Sertoli cell function: lessons from SCCx43KO mice.

- 30 *Reproduction* **151**, R15-27, doi:10.1530/REP-15-0366 (2016).
- 31 30 Weider, K. *et al.* Altered differentiation and clustering of Sertoli cells in transgenic mice showing a Sertoli cell specific
32 knockout of the connexin 43 gene. *Differentiation* **82**, 38-49, doi:10.1016/j.diff.2011.03.001 (2011).
- 33 31 Günther, S., Fietz, D., Weider, K., Bergmann, M. & Brehm, R. Effects of a murine germ cell-specific knockout of
34 Connexin 43 on Connexin expression in testis and fertility. *Transgenic Research* **22**, 631-641,
35 doi:10.1007/s11248-012-9668-1 (2013).
- 36 32 Defamie, N. *et al.* Impaired gap junction connexin43 in Sertoli cells of patients with secretory azoospermia: a marker of
37 undifferentiated Sertoli cells. *Lab Invest* **83**, 449-456 (2003).
- 38 33 Brehm, R. *et al.* Altered expression of connexins 26 and 43 in Sertoli cells in seminiferous tubules infiltrated with
39 carcinoma-in-situ or seminoma. *The Journal of pathology* **197**, 647-653, doi:10.1002/path.1140 (2002).
- 40 34 Franke, F. E. *et al.* Differentiation markers of Sertoli cells and germ cells in fetal and early postnatal human testis.
41 *Anatomy and embryology* **209**, 169-177 (2004).
- 42 35 Sharpe, R. M., McKinnell, C., Kivlin, C. & Fisher, J. S. Proliferation and functional maturation of Sertoli cells, and their
43 relevance to disorders of testis function in adulthood. *Reproduction* **125**, 769-784 (2003).
- 44 36 Bouma, G. J., Hudson, Q. J., Washburn, L. L. & Eicher, E. M. New Candidate Genes Identified for Controlling Mouse
45 Gonadal Sex Determination and the Early Stages of Granulosa and Sertoli Cell Differentiation. *Biology of Reproduction*
46 **82**, 380-389, doi:10.1095/biolreprod.109.079822 (2010).
- 47 37 Boyer, A., Lussier, J. G., Sinclair, A. H., McClive, P. J. & Silversides, D. W. Pre-Sertoli specific gene expression profiling
48 reveals differential expression of Ppt1 and Brd3 genes within the mouse genital ridge at the time of sex determination.
49 *Biology of Reproduction* **71**, 820-827, doi:10.1095/biolreprod.104.029371 (2004).
- 50 38 Mincheva, M. *et al.* Reassembly of adult human testicular cells: can testis cord-like structures be created in vitro?
51 *Molecular human reproduction*, doi:10.1093/molehr/gax063 (2017).
- 52 39 Wang, H. *et al.* Establishment and applications of male germ cell and Sertoli cell lines. *Reproduction* **152**, R31-40,
53 doi:10.1530/rep-15-0546 (2016).
- 54 40 Kanatsushinohara, M. *et al.* Reconstitution of Mouse Spermatogonial Stem Cell Niches in Culture. *Cell Stem Cell* **11**,
55 567 (2012).
- 56 41 Cools, M., Wolffenbuttel, K. P., Drop, S. L. S., Oosterhuis, J. W. & Looijenga, L. H. J. Gonadal Development and Tumor
57 Formation at the Crossroads of Male and Female Sex Determination. *Sexual Development* **5**, 167-180,
58 doi:10.1159/000329477 (2011).
- 59 42 Gorga, A. *et al.* PPAR γ activation regulates lipid droplet formation and lactate production in rat Sertoli cells. *Cell &*
60 *Tissue Research*, 1-14 (2017).
- 61 43 Wang, H. *et al.* Evaluation on the phagocytosis of apoptotic spermatogenic cells by Sertoli cells in vitro through detecting
62 lipid droplet formation by Oil Red O staining. *Reproduction* **132**, 485-492, doi:10.1530/rep.1.01213 (2006).
- 63 44 Chui, K. *et al.* Characterization and Functionality of Proliferative Human Sertoli Cells. *Cell Transplantation* **20**, 619-635,
64 doi:10.3727/096368910x536563 (2011).
- 65 45 Lecureuil, C., Fontaine, I., Crepieux, P. & Guillou, F. Sertoli and granulosa cell-specific Cre recombinase activity in
66 transgenic mice. *Genesis* **33**, 114-118, doi:10.1002/gene.10100 (2002).
- 67 46 Barbara, P. D. S. *et al.* Direct Interaction of SRY-Related Protein SOX9 and Steroidogenic Factor 1 Regulates
68 Transcription of the Human Anti-Müllerian Hormone Gene. *Molecular & Cellular Biology* **18**, 6653 (1998).
- 69 47 Johnston, D. S. *et al.* Stage-specific gene expression is a fundamental characteristic of rat spermatogenic cells and Sertoli
70 cells. *Proceedings of the National Academy of Sciences of the United States of America* **105**, 8315-8320,
71 doi:10.1073/pnas.0709854105 (2008).
- 72 48 Jenna T. Haverfield, P. G. S., and Sarah J. Meachem. in *Sertoli Cell Biology (Second Edition)* (ed Michael D.
73 Griswold) Ch. 14, 409-436 (Elsevier, 2015).
- 74 49 Nagano, M., McCarrey, J. R. & Brinster, R. L. Primate spermatogonial stem cells colonize mouse testes. *Biol. Reprod* **64**,
75 1409-1416 (2001).
- 76 50 Jung, D. *et al.* In vitro differentiation of human embryonic stem cells into ovarian follicle-like cells. *Nat Commun* **8**,

- 37 15680, doi:10.1038/ncomms15680 (2017).
- 38 51 Kaur, G., Thompson, L. A. & Dufour, J. M. Sertoli cells - Immunological sentinels of spermatogenesis. *Seminars in Cell*
39 *and Developmental Biology* **30**, 36-44, doi:10.1016/j.semcdb.2014.02.011 (2014).
- 40 52 Selawry, H. P., Kotb, M., Herrod, H. G. & Lu, Z. N. Production of a factor, or factors, suppressing IL-2 production and T
41 cell proliferation by Sertoli cell-enriched preparations. A potential role for islet transplantation in an immunologically
42 privileged site. *Transplantation* **52**, 846 (1991).
- 43 53 Yin, Z. Z. *et al.* Cotransplantation With Xenogenetic Neonatal Porcine Sertoli Cells Significantly Prolongs Islet Allograft
44 Survival in Nonimmunosuppressive Rats. *Transplantation* **88**, 339-345, doi:10.1097/TP.0b013e3181ae5dcf (2009).
- 45
- 46

47 **AUTHOR CONTRIBUTIONS**

48 J.L., N.W., J.D., Y.G. and L.L. carried out all the experiments; J.H. and J.L. conducted all bioinformatics analysis, J.L.
49 and K.K. designed experiments and wrote the manuscript.

50 **ACKNOWLEDGMENTS**

51 We are indebted to Prof. Zuping He for giving us the primary human Sertoli cells. Research funding is provided by the
52 Ministry of Science and Technology of China [2018YFA0107703; 2017YFC1001601]; and Cross-discipline
53 Foundation of Tsinghua University.

54

55 **Methods**

56 **Human ES cell culturing and fibroblast differentiation**

57 Human ES cell line used in this study were H1 (XY) and H9 (XX), purchased from WiCell, Inc. Undifferentiated H1 and
58 H9 were maintained on MEF feeder cells as previous described¹. All cells were cultured at 37°C in a humidified incubator
59 supplied with 5% CO₂. ES medium were standard knockout serum replacer (KSR) consisted of 20% knockout serum
60 replacer, 0.1mM nonessential amino acids, 1mM L-glutamine, 0.1mM -mercaptoethanol, and 4 ng/ml recombinant human
61 basic fibroblast growth factor (bFGF, R&D systems).

62 To obtain adherent fibroblast differentiation, human ESC clones were first transferred to 1% Matrigel coated plates by
63 colony picking using a glass needle and cultured in ES cell conditioned medium (ES medium incubated overnight on
64 irradiated MEFs) for ~5 days to remove all the residual MEF cells. Differentiation of hESCs to fibroblasts (dH1) began after
65 aspirating of conditioned media, washing with PBS without Ca²⁺ and Mg²⁺ twice, and replacing with differentiation media
66 (knockout DMEM with 20% fetal bovine serum, 0.1mM nonessential amino acids, 1mM L-glutamine). Differentiation
67 media was changed every 3 days. When the cell reached 90% confluency (~7 days), the resulting dH1 were collected and
68 kept in liquid nitrogen tank for long time preservation or passaged by the ratio 1:3 if more cells was needed.

69 **Human pulmonary fibroblasts and adult Sertoli cells culturing**

71 Human pulmonary fibroblasts (HPF) were purchased from National Infrastructure of Cell Line Resource. Human adult
72 Sertoli cells were a generous gift from Dr. Zuping He of Shanghai Jiao Tong University. The HPF cells were maintained at
73 75 ml culture flask in 15 ml DMEM culture medium (Corning) containing 10% FBS (Gibco), 0.1 mM nonessential amino
74 acids and 1 mM L-glutamine. As for primary adult Sertoli cells, they were procured and cultured as previously described²
75 in DF12 medium consisting of DMEM/F12 and 10% FBS (Gibco) and passaged every 5 days when cell confluence reached
76 80%. All of the cells above were cultured in a 37 °C humidified incubator supplied with 5% CO₂.

77 **Overexpression vector construction and lentivirus Production**

79 All overexpression vectors carrying EF1 α promoter and desired gene were constructed using the Gateway system
80 (Invitrogen) as previously described¹. Briefly, the candidate cDNA was first introduced into pENTR/1A or pENTR/D-topo
81 donor vectors and transferred to 2K7 destination vectors with EF1 α promoter in pENTR/5' topo by LR recombination³.
82 Modified destination plasmids containing the cDNA were then introduced into 293FT cells together with the helper
83 plasmids vsvg and Δ 8.9 by LIPO3000 (Invitrogen) transfection to produced virus. Approximately, a total of 37 ml of virus
84 supernatant was harvested on day1 and day3 after transfection and filtered with a 0.45 μ m filter. At the time of virus
85 infection, 8 μ g/ml of polybrene was supplemented to increase infection efficiency.

86 **AMH:EGFP reporter and creating reporter cell line**

88 1.6 kb of human AMH promoter was PCR amplified from genomic DNA of 293FT cells and cloned to pENTR5'-TOPO.
89 Cloned plasmids were then recombined with pENTR/D-TOPO that carried the EGFP cDNA to create p2K7-AMH:EGFP
90 recombinant plasmid and generated lentiviral supernatant as described above in overexpression vector construction section.
91 Fibroblast HPF or dH1 in early passage (with 50% confluence) were transduced overnight on plate in fibroblast medium
92 and recovered for one day after removal of virus. Subsequent drug selection by blasticidin (10 μ g/ml) required another 3
93 days. Selected human fibroblasts were passaged for two times to expand the cell number for further experiments or frozen
94 in liquid nitrogen.

95 **hiSC reprogramming and enrichment by FACS**

97 Sertoli-like cell reprogramming was carried out in flask. In brief, human fibroblast cells carrying AMH reporter were seeded
98 1 day prior to overnight transduction with lentivirus NR5A1, GATA4, DMRT1, SOX9 and WT1 (for 5F-hiSCs) or NR5A1
99 and GATA4 (for 2F-hiSCs), recovered for 24 hours, following by drug selection with geneticin (1 mg/ml) for 5 days. After
100 drug selection, transduced cells were cultured in hiSCs medium, maintained for the indicated reprogramming duration, and

31 harvested for FACS by digestion with TrypLE Express (Invitrogen). The single cell suspension for FACS was prepared with
32 MACS medium (10% FBS in PBS with 0.0125 mM EDTA) and filtrated through a BD cell sorter. Cell sorting was
33 proceeded on a high-speed cell sorter (Influx, BD) and was sorted to collecting tube containing DF12 medium.
34 Experiment aiming at examining different combinations of reprogramming factors was performed in 6 well plates and all
35 possible combinations of NR5A1, GATA4, DMRT1, SOX9 and WT1 were tested (See table S2).

36 37 **Quantitative PCR and statistical analysis**

38 Quantitative PCR was conducted as previously described¹. Briefly, total RNA was collected according to the instructions
39 provided by QIAGEN RNeasy kit (QIAGEN) or TRIZOL (Invitrogen). CDNA was generated by EasyScript One-Step
40 gDNA Removal and cDNA Synthesis SuperMix kit (TRANSGEN) according to manufacturer's protocols using up to 500
41 ng RNA for each sample. 20 μ l reaction (for Bio-rad 96-well System) were prepared and conducted with TransStart Green
42 qPCR SuperMix kit (TRANSGEN). Gene expression was calculated using Bio-Rad CFX Manager program for relative
43 expression formulation (dC(t)) and normalized to housekeeping genes (ACTB or GAPDH). Then, the gene expression of
44 different samples were again normalized to the expression of control cells infected by p2k7 empty virus (CTRL) and
45 reported as fold change⁴. Statistical analysis was carried out using Student's t-test or one-way ANOVA by Prism 6.0
46 software.

47 **RNA sequencing**

48 ~2.5 $\times 10^5$ cells were collected by FACS and total RNA was extracted by TRIZOL (Invitrogen). The quality and integrity of
49 the purified RNAs was checked by Agilent 2100 bioanalyzer. Qualified RNA from the following samples was used for RNA
50 Sequencing analysis: (1) HPF or dH1 carrying AMH:EGFP reporter, transduced with empty virus p2k7 and followed the
51 same reprogramming procedure as described above. (2) Day10 hiSCs generated with 5 factors (5F-hiSCs) or generated from
52 2 factors (2F-hiSCs). (3) Human primary adult Sertoli cells (aSCs) cultured *in vitro* in DMEMF12 medium + 10% FBS.
53 Sequencing libraries preparation and sequencing operations were carried out by ANNOROAD, a company providing RNA
54 sequencing service, complied with the whole set of processes from Illumina.

55 **RNA-seq data processing.**

56 All RNA-seq data were mapped to human genome build hg19 (UCSC) by TopHat (version 2.1.1), reads from PCR
57 duplicates were dropped. The gene expression level was calculated by Cufflinks (version 2.2.1) using the protein coding
58 genes GTF file extracted from Ensembl database (Homo_sapiens.GRCh37.75.gtf). Read counts were obtained using HTSeq
59 (version 0.9.1). Differentially expressed genes (DEGs) were analyzed using R package DESeq2 and selected using p-value
60 < 0.01 as a threshold. Heat map was plotted using heatmap.2 function of R, and gene expressions were scaled to FPKM or
61 Z-scores. We used R function cor to do sample correlation clustering and K-means clustering was performed using Cluster
62 3.0 package (K = 3, Spearman Correlation, Complete-linkage) and clustered heat maps were produced by TreeView.

63 **Immunofluorescence of cultured cells**

64 Dissociated cells from FACS enrichment were collected onto a slide by Cytospin (800 r.p.m. for 5 min) or replated onto a
65 6-well plate. After that, cells were washed 1 time with PBS, fixed in 4% paraformaldehyde for 10 minutes and treated with
66 2.5% Triton X-100 for 15 minutes. For antibodies staining, slides were first blocked in 2.5% donkey serum for 1 hour, then
67 incubated overnight in 4°C with primary antibody (1:200 for KRT18, 1:100 for NuMA, 1:200 for CX43, 1:100 for VASA,
68 all rabbit-derived, Abcam; 1:50 for DAZL, mouse-derived, Bio-Rad; 1:100 for NR5A1, GATA4, WT1, SOX9, DMRT1, all
69 rabbit-derived, Proteintech). Slides were then washed five times (each 3 minutes) with PBST (0.1% Tween-20/PBS),
70 followed by anti-rabbit secondary antibodies (anti-rabbit-555 or anti-rabbit-488, Invitrogen) incubating for 1 hour at room
71 temperature and washing for another 5 times. All sections were then mounted with Prolong Diamond Anti-Fade Mounting
72 Reagent (ThermoFisher) and cover slip.

73 **Effect of 2F-hiSCs conditioned medium on Jurkat cell proliferation and IL-2 production**

48 1 ml conditioned medium were collected from 3.5×10^4 of 2F-hiSCs or dH1-2K7 fibroblast (control) cultured at 50%
49 confluence 48 h after plating. For each assay, 2×10^4 human T lymphocytes (Jurkat E6-1 cells, gift from Professor Hai Qi,
50 Tsinghua University) were seeded in 1 well of 96-well plate with 120 μ l 1064 medium with 10% FBS, 0.1mM nonessential
51 amino acids, 1mM L-glutamine, 0.1mM-mercaptoethanol and added with indicated amount of conditioned medium from
52 either 2F-hiSCs or dH1-2K7 (as control). The Jurkat cells were then cultured in a 37°C incubator with 5% CO₂ for 3 days.
53 Metabolism of WST-1 was used to determine the proliferative ability of lymphocytes in each well according to
54 manufacturer's instructions (Beyotime, Co., Ltd.). Three hours prior to analysis, 12 μ l of WST-1 was added to each well and
55 the final absorbance was measured by a microplate reader at 450 nm (SPECTRA max PLUS, Molecular Devices Inc.). 1064
56 medium alone with WST-1 was used as a control to subtract background absorbance. For IL-2 quantification, 2×10^5 of
57 Jurkat cells were seeded in one 6-well plate containing either 50% 2F-hiSCs or dH1-2K7 conditioned medium and cultured
58 for 3 days. Then, cells were collected and lysed with 20 μ l RIPA buffer. The concentration of IL-2 was determined by
59 ELISA kit according to the manufacturer's instructions (Cusabio Biotech, Co., Ltd.).
50

51 **Cell migration assays**

52 Confluent P8 HUVEC cells (a gift from Professor Jie Na, Tsinghua university) were cultured with fresh ECM medium
53 (Sciencell) overnight before experiment. Then cells were incubated with medium containing 2.5 μ M Calcein-AM
54 fluorescent dye for one hour in incubator supplied with 37°C, 5% CO₂. Cells were then trypsinized, counted and suspended
55 in migration medium (50% ECM+50% MEF medium). Migration assays were carried out in Corning FluoroBlok
56 24-multiwell insert plate with 8.0 μ m pores (Cat. No. 351157, Corning). Prior to seeding HUVEC (150 k, in 100 μ l volume)
57 into the insert, 50 % conditioned medium pre-incubated with hiSCs or dH1 was mixed with 50% ECM and added to the
58 basal chamber (600 μ l in total). Following incubation of HUVECs at 37°C, 5% CO₂ needed for 20 hours. The migration
59 cells passed through the membrane were monitored by Calcein-AM with the help of an inverted microscope (Leica™) at
60 485/535 nm (Ex/Em). Images were captured using Leica-Pro software provided by the microscope company. The number of
61 migration cell was measured by calculating of the Calcein-AM green signal of each image.
62

63 **Mouse PGC isolation and coculture with 2F-hiSCs**

64 Mouse spermatogonia cells were isolated from ~24 testis of C57BL/6 mice at day 6 after birth according to previous
65 protocol with minor modifications⁵. Briefly, the decapsulated testis and seminiferous tubules were detached with the help
66 of tweezers. After washing with DPBS for 3 times, the seminiferous tubules were transferred to a new 15 ml tube and
67 subjected to enzymatic digestion. First, the seminiferous tubules were digested with 1mg/ml collagenase IV for 5 min at
68 37°C in a water bath with shaking, then centrifuged at 50 \times g to collect the segregated tubules and washed 3 times with
69 DMEM/F12 medium. Completed disintegration of the tubules were achieved by treating with 0.25% trypsin for 5 min at
70 37°C with gentle shaking and pipetting. The suspension, containing primarily Sertoli cells, peritubular cell and male germ
71 cells, was then pelleted at 500 \times g for 5 min at room temperature and washed once. Finally, cells were resuspended in 2 ml
72 culture medium composed of DMEM/F12 medium with 10% FBS and seeded on 2 well of 6-well plates (Corning) and
73 incubated at incubator supplied with 37°C, 5% CO₂. After attachment for 24 hours, the somatic cells were tightly attached
74 to the dish and formed patches, while some of the spermatogonia cells were just loosely attached on the somatic cells. 24
75 hours prior to coculture experiments, $\sim 1.5 \times 10^5$ dH1 or 2F-hiSCs were plated to 1 well of the 48 well plate. The
76 spermatogonia cells were collected by gently washing with fresh media and transferred to the well plated with the dH1 or
77 2F-hiSCs in DMEMF/F12 medium with 10% FBS.
78

79 **Co-transplantation of hiSCs with 293FT cells**

80 All animal experiments were approved by the Institutional Animal Care and Use Committees at Tsinghua University. $\sim 1.3 \times$
81 10^6 number of 293FT cells stably transduced with a luciferase reporter were mixed with 2.5×10^5 cells of either dH1 or
82 2F-hiSCs in 100 μ l Matrigel. The suspension was transplanted into C57B6/6J (Purchased from Charles River Laboratories)
83 mice with normal immune system by subcutaneous injection. Live imaging of transplanted mice was performed at the
84 indicative day after transplantation. 15 minutes prior to live imaging, 100 μ l of D-luciferin (15mg/ml, 10 μ L/g mouse

35 weight) was injected to the mice by intraperitoneal injection and luciferase activity was measured in the IVIS Spectrum
36 machine (PerkinElmer Health Sciences, Inc.).

37

38 References (Method)

- 39 1 Koopman, P., Münsterberg, A., Capel, B., Vivian, N. & Lovellbadge, R. Expression of a candidate sex-determining gene
40 during mouse testis differentiation. *Nature* **348**, 450-452 (1990).
- 41 2 Bott, R. C., Mcfee, R. M., Clopton, D. T., Toombs, C. & Cupp, A. S. Vascular endothelial growth factor and kinase domain
42 region receptor are involved in both seminiferous cord formation and vascular development during testis
43 morphogenesis in the rat. *Biology of reproduction* **75**, 56 (2006).
- 44 3 Brennan, J., Tilmann, C. & Capel, B. Pdgfr-alpha mediates testis cord organization and fetal Leydig cell development in
45 the XY gonad. *Genes & Development* **17**, 800-810 (2003).
- 46 4 Barrionuevo, F. *et al.* Testis cord differentiation after the sex determination stage is independent of Sox9 but fails in the
47 combined absence of Sox9 and Sox8. *Developmental Biology* **327**, 301-312, doi:10.1016/j.ydbio.2008.12.011 (2009).
- 48 5 Moniot, B. *et al.* The PGD2 pathway, independently of FGF9, amplifies SOX9 activity in Sertoli cells during male sexual
49 differentiation. *Development* **136**, 1813-1821, doi:10.1242/dev.032631 (2009).
- 50 6 Yao, H. H., Ungewitter, E., Franco, H. & Capel, B. in *Sertoli Cell Biology, Second Edition* (ed Michael D. Griswold) Ch.
51 Establishment of fetal Sertoli cells and their role in testis morphogenesis, (Elsevier, 2015).
- 52 7 Griswold, M. D. The central role of Sertoli cells in spermatogenesis. *Semin Cell Dev Biol* **9**, 411-416,
53 doi:10.1006/scdb.1998.0203 (1998).
- 54 8 McLaren, A. Germ and somatic cell lineages in the developing gonad. *Molecular and cellular endocrinology* **163**, 3-9
55 (2000).
- 56 9 Oatley, J. M. & Brinster, R. L. The germline stem cell niche unit in mammalian testes. *Physiological Reviews* **92**, 577-595
57 (2012).
- 58 10 Hai, Y. *et al.* The roles and regulation of Sertoli cells in fate determinations of spermatogonial stem cells and
59 spermatogenesis. *Seminars in Cell & Developmental Biology* **29**, 66-75,
60 doi:<http://dx.doi.org/10.1016/j.semcdb.2014.04.007> (2014).
- 61 11 Kaur, G., Thompson, L. A. & Dufour, J. M. Therapeutic potential of immune privileged Sertoli cells. **12**, 105-117 (2015).
- 62 12 Mital, P., Kaur, G. & Dufour, J. M. Immunoprotective sertoli cells: making allogeneic and xenogeneic transplantation
63 feasible. *Reproduction* **139**, 495 (2010).
- 64 13 Valdés González, R. A. *et al.* Xenotransplantation of porcine neonatal islets of Langerhans and Sertoli cells: a 4-year study.
65 *European Journal of Endocrinology* **153**, 419-427 (2005).
- 66 14 Luca, G. *et al.* Sertoli cells for cell transplantation: pre-clinical studies and future perspectives. *Andrology*,
67 doi:10.1111/andr.12484 (2018).
- 68 15 Zhou, Q. *et al.* Complete Meiosis from Embryonic Stem Cell-Derived Germ Cells In Vitro. *Cell Stem Cell* (2016).
- 69 16 Kee, K., Angeles, V. T., Flores, M., Nguyen, H. N. & Reijo Pera, R. A. Human DAZL, DAZ and BOULE genes modulate
70 primordial germ-cell and haploid gamete formation. *Nature* **462**, 222-225, doi:10.1038/nature08562 (2009).
- 71 17 Easley, C. A. *t. et al.* Direct differentiation of human pluripotent stem cells into haploid spermatogenic cells. *Cell reports*
72 **2**, 440-446, doi:10.1016/j.celrep.2012.07.015 (2012).
- 73 18 Kulibin, A. Y. & Malolina, E. A. Only a small population of adult Sertoli cells actively proliferates in culture. *Reproduction*
74 **152**, 271-281, doi:10.1530/rep-16-0013 (2016).
- 75 19 Chaudhary, J., Sadler-Riggelman, I., Ague, J. M. & Skinner, M. K. The helix-loop-helix inhibitor of differentiation (ID)
76 proteins induce post-mitotic terminally differentiated sertoli cells to re-enter the cell cycle and proliferate. *Biology of*
77 *Reproduction* **72**, 1205-1217, doi:10.1095/biolreprod.104.035717 (2005).
- 78 20 Cherry, A. B. & Daley, G. Q. Reprogramming cellular identity for regenerative medicine. *Cell* **148**, 1110-1122 (2012).
- 79 21 Xu, J., Du, Y. & Deng, H. Direct Lineage Reprogramming: Strategies, Mechanisms, and Applications. *Cell Stem Cell* **16**, 119
80 (2015).
- 81 22 Yamanaka, S. & Blau, H. M. Nuclear reprogramming to a pluripotent state by three approaches. *Nature* **465**, 704 (2010).

- 42 23 Nam, Y. J. *et al.* Reprogramming of human fibroblasts toward a cardiac fate. *Proceedings of the National Academy of*
43 *Sciences* **110**, 5588 (2013).
- 44 24 Huang, P. *et al.* Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. *Cell Stem Cell* **14**,
45 370-384, doi:10.1016/j.stem.2014.01.003 (2014).
- 46 25 Hendry, C. E. *et al.* Direct transcriptional reprogramming of adult cells to embryonic nephron progenitors. *Journal of the*
47 *American Society of Nephrology* **24**, 1424-1434 (2013).
- 48 26 Buganim, Y. *et al.* Direct Reprogramming of Fibroblasts into Embryonic Sertoli-like Cells by Defined Factors. *Cell Stem Cell*
49 **11**, 373-386, doi:10.1016/j.stem.2012.07.019 (2012).
- 50 27 Brehm, R. *et al.* A sertoli cell-specific knockout of connexin43 prevents initiation of spermatogenesis. *Am J Pathol* **171**,
51 19-31, doi:10.2353/ajpath.2007.061171 (2007).
- 52 28 Sridharan, S. *et al.* Proliferation of adult Sertoli cells following conditional knockout of the gap junctional protein GJA1
53 (Connexin 43) in mice. *Biology of Reproduction* **76**, 804-812, doi:10.1095/biolreprod.106.059212 (2007).
- 54 29 Gerber, J., Heinrich, J. & Brehm, R. Blood-testis barrier and Sertoli cell function: lessons from SCCx43KO mice.
55 *Reproduction* **151**, R15-27, doi:10.1530/REP-15-0366 (2016).
- 56 30 Weider, K. *et al.* Altered differentiation and clustering of Sertoli cells in transgenic mice showing a Sertoli cell specific
57 knockout of the connexin 43 gene. *Differentiation* **82**, 38-49, doi:10.1016/j.diff.2011.03.001 (2011).
- 58 31 Günther, S., Fietz, D., Weider, K., Bergmann, M. & Brehm, R. Effects of a murine germ cell-specific knockout of Connexin
59 43 on Connexin expression in testis and fertility. *Transgenic Research* **22**, 631-641, doi:10.1007/s11248-012-9668-1
60 (2013).
- 61 32 Defamie, N. *et al.* Impaired gap junction connexin43 in Sertoli cells of patients with secretory azoospermia: a marker of
62 undifferentiated Sertoli cells. *Lab Invest* **83**, 449-456 (2003).
- 63 33 Brehm, R. *et al.* Altered expression of connexins 26 and 43 in Sertoli cells in seminiferous tubules infiltrated with
64 carcinoma-in-situ or seminoma. *The Journal of pathology* **197**, 647-653, doi:10.1002/path.1140 (2002).
- 65 34 Franke, F. E. *et al.* Differentiation markers of Sertoli cells and germ cells in fetal and early postnatal human testis.
66 *Anatomy and embryology* **209**, 169-177 (2004).
- 67 35 Sharpe, R. M., McKinnell, C., Kivlin, C. & Fisher, J. S. Proliferation and functional maturation of Sertoli cells, and their
68 relevance to disorders of testis function in adulthood. *Reproduction* **125**, 769-784 (2003).
- 69 36 Bouma, G. J., Hudson, Q. J., Washburn, L. L. & Eicher, E. M. New Candidate Genes Identified for Controlling Mouse
70 Gonadal Sex Determination and the Early Stages of Granulosa and Sertoli Cell Differentiation. *Biology of Reproduction*
71 **82**, 380-389, doi:10.1095/biolreprod.109.079822 (2010).
- 72 37 Boyer, A., Lussier, J. G., Sinclair, A. H., McClive, P. J. & Silversides, D. W. Pre-Sertoli specific gene expression profiling
73 reveals differential expression of Ppt1 and Brd3 genes within the mouse genital ridge at the time of sex determination.
74 *Biology of Reproduction* **71**, 820-827, doi:10.1095/biolreprod.104.029371 (2004).
- 75 38 Mincheva, M. *et al.* Reassembly of adult human testicular cells: can testis cord-like structures be created in vitro?
76 *Molecular human reproduction*, doi:10.1093/molehr/gax063 (2017).
- 77 39 Wang, H. *et al.* Establishment and applications of male germ cell and Sertoli cell lines. *Reproduction* **152**, R31-40,
78 doi:10.1530/rep-15-0546 (2016).
- 79 40 Kanatsushinohara, M. *et al.* Reconstitution of Mouse Spermatogonial Stem Cell Niches in Culture. *Cell Stem Cell* **11**, 567
80 (2012).
- 81 41 Cools, M., Wolffenbuttel, K. P., Drop, S. L. S., Oosterhuis, J. W. & Looijenga, L. H. J. Gonadal Development and Tumor
82 Formation at the Crossroads of Male and Female Sex Determination. *Sexual Development* **5**, 167-180,
83 doi:10.1159/000329477 (2011).
- 84 42 Gorga, A. *et al.* PPAR γ activation regulates lipid droplet formation and lactate production in rat Sertoli cells. *Cell & Tissue*
85 *Research*, 1-14 (2017).
- 86 43 Wang, H. *et al.* Evaluation on the phagocytosis of apoptotic spermatogenic cells by Sertoli cells in vitro through
87 detecting lipid droplet formation by Oil Red O staining. *Reproduction* **132**, 485-492, doi:10.1530/rep.1.01213 (2006).
- 88 44 Chui, K. *et al.* Characterization and Functionality of Proliferative Human Sertoli Cells. *Cell Transplantation* **20**, 619-635,

- 39 doi:10.3727/096368910x536563 (2011).
- 30 45 Kaur, G., Thompson, L. A. & Dufour, J. M. Sertoli cells - Immunological sentinels of spermatogenesis. *Seminars in Cell and*
31 *Developmental Biology* **30**, 36-44, doi:10.1016/j.semcdb.2014.02.011 (2014).
- 32 46 Lecureuil, C., Fontaine, I., Crepieux, P. & Guillou, F. Sertoli and granulosa cell-specific Cre recombinase activity in
33 transgenic mice. *Genesis* **33**, 114-118, doi:10.1002/gene.10100 (2002).
- 34 47 Barbara, P. D. S. *et al.* Direct Interaction of SRY-Related Protein SOX9 and Steroidogenic Factor 1 Regulates Transcription
35 of the Human Anti-Müllerian Hormone Gene. *Molecular & Cellular Biology* **18**, 6653 (1998).
- 36 48 Johnston, D. S. *et al.* Stage-specific gene expression is a fundamental characteristic of rat spermatogenic cells and Sertoli
37 cells. *Proceedings of the National Academy of Sciences of the United States of America* **105**, 8315-8320,
38 doi:10.1073/pnas.0709854105 (2008).
- 39 49 Jenna T. Haverfield, P. G. S., and Sarah J. Meachem. in *Sertoli Cell Biology (Second Edition)* (ed Michael D. Griswold)
40 Ch. 14, 409–436 (Elsevier, 2015).
- 41 50 Nagano, M., McCarrey, J. R. & Brinster, R. L. Primate spermatogonial stem cells colonize mouse testes. *Biol. Reprod* **64**,
42 1409-1416 (2001).
- 43 51 Jung, D. *et al.* In vitro differentiation of human embryonic stem cells into ovarian follicle-like cells. *Nat Commun* **8**, 15680,
44 doi:10.1038/ncomms15680 (2017).
- 45 52 Selawry, H. P., Kotb, M., Herrod, H. G. & Lu, Z. N. Production of a factor, or factors, suppressing IL-2 production and T cell
46 proliferation by Sertoli cell-enriched preparations. A potential role for islet transplantation in an immunologically
47 privileged site. *Transplantation* **52**, 846 (1991).
- 48 53 Yin, Z. Z. *et al.* Cotransplantation With Xenogenetic Neonatal Porcine Sertoli Cells Significantly Prolongs Islet Allograft
49 Survival in Nonimmunosuppressive Rats. *Transplantation* **88**, 339-345, doi:10.1097/TP.0b013e3181ae5dcf (2009).
- 50 54 Guo, Y. *et al.* Long-term culture and significant expansion of human Sertoli cells whilst maintaining stable global
51 phenotype and AKT and SMAD1/5 activation. *Cell communication and signaling : CCS* **13**, 20,
52 doi:10.1186/s12964-015-0101-2 (2015).
- 53 55 Suter, D. M. *et al.* Rapid generation of stable transgenic embryonic stem cell lines using modular lentivectors. *Stem Cells*
54 **24**, 615-623 (2010).
- 55 56 Vandesompele, J. *et al.* Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple
56 internal control genes. *Genome Biology* **3** (2002).
- 57 57 Kanatsu-Shinohara, M. *et al.* Long-term proliferation in culture and germline transmission of mouse male germline stem
58 cells. *Biol Reprod* **69**, 612-616, doi:10.1095/biolreprod.103.017012 (2003).

19

20

21

Figure 1




Figure 1. Induction of Sertoli-like cells (hiSCs) from human fibroblasts

- (a) Immunostaining of NR5A1, GATA4, WT1, SOX9 and DMRT1 in human fibroblasts (HPF) 3 days post infection. DAPI was used to indicate nucleus. Scale bar, 25 μ m.
- (b) Experimental design for the reprogramming of human Sertoli-like cells (hiSCs). Human fibroblasts were infected with lentivirus carrying human transcription factors: NR5A1, GATA4, WT1, SOX9 and DMRT1 (5TFs, Table S1). The culture medium was changed to MEF medium 1 day after infection and followed by G418 selection for 5 days, then changed to DFMEM/F12 medium. hiSCs were characterized 10-14 days post viral transduction.
- (c) Schematic protocol for the reprogramming and isolation of AMH positive Sertoli-like cells. An AMH:EGFP reporter was integrated to the fibroblasts for cell sorting.
- (d) FACS analysis of AMH:EGFP+ cell at day 10 after 5TFs infection, the percentage of EGFP+ cell was used to determine the induction efficiency. Two types of human fibroblasts (HPF and dH1) were tested. Cells infected by p2k7 empty vector were used as negative control (CTRL).
- (e) Morphology of AMH:EGFP+ hiSCs after FACS. Scale bars, 20 μ m.
- (f) The mRNA level of *AMH* was enriched in AMH:EGFP+ hiSCs compared to the control group as measured by quantitative PCR. n=3, technical replicates of $\sim 5 \times 10^4$ cells were collected by FACS. All data are presented as means \pm SD. *p < 0.01; **p < 0.05. > 3 independent experiments were carried out.
- (g) Immunofluorescent staining of KRT18 in AMH:EGFP+ hiSCs and dH1 infected by p2k7 empty virus (CTRL) after FACS. Scale bar, 50 μ m.

Figure 2




Figure 2. Whole genome transcriptional profiling of AMH:EGFP+ hiSCs

(a) Venn diagram to display differentially expressed genes (DEGs, FPKM value, fold change > 2) between dH1-2K7_vs_aSCs (n=2) and dH1-2K7_vs_5F-hiSCs (n=2). Intersection part represented the number of co-differentially expressed genes (CO-DEGs).

(b) Upregulated and downregulated DEGs in (a). X axis indicates upregulated DEGs and downregulated DEGs. Y axis represented DEGs numbers. Comparing samples were shown by different colors. Black bar represented dH1-2K7_vs_5F-hiSCs. Gray bar represented dH1-2K7_vs_aSCs.

(c) Upregulated and downregulated CO-DEGs in (a). X axis indicates CO-DEGs numbers. Red bar indicates co-upregulated DEGs, green bar indicates co-downregulated DEGs. Brown and gray bar indicate CO-DEGs in opposite trend of upregulation and downregulation respectively.

(d) Heat map of gene expression of dH1-2K7, 5F-hiSCs and aSCs (n=2, two independent samples were subjected to RNA-seq). Red indicated upregulated expression, green indicated down-regulated expression.

(e) Functional enrichment analysis, biological processes of 1973 and 1314 differentially expressed genes were showed.

(f) The mRNA level of Sertoli-cell markers in AMH:EGFP- cells and AMH:EGFP+ cells as measured by qPCR. Fold expression was normalized to the levels of dH1 infected by empty virus p2k7 (CTRL). GAPDH was used as the housekeeping gene for normalization. All data are presented as means \pm SD, n=2, 3 independent experiments were carried out.

Figure 3




Figure 3. NR5A1 and GATA4 are sufficient to derive hiSCs

(a) Representative FACS results of different combinations of NR5A1, GATA4, WT1, SOX9 and DMRT1 for the induction of AMH:EGFP+ cells. dH1 fibroblasts were transduced with the indicated factors and reprogrammed for 10 days. The combinations were divided into three groups: -NR5A1, combinations without NR5A1; +NR5A1, combinations with NR5A1 but without GATA4; +NR5A1 & GATA4, combinations with both NR5A1 and GATA4.

(b) Quantitative data of EGFP+ cells in (a) (n=2, biological replicates, error bar indicates SD), 3 independent combination experiments were conducted. $\sim 10^4$ cells were FACS in each experiment.

(c) Immunofluorescent staining of KRT18 in 2F-hiSCs and dH1-2K7 (CTRL) after FACS. Scale bar, 100 μ m.

(d) Heat map of RNA-seq data illustrating differentially co-expressed genes. Red indicates upregulated expression, whereas green indicates downregulated expression. The genes were divided into three groups: Genes upregulated in 2F-hiSCs (dH1), 5F-hiSCs (dH1) and aSCs; genes downregulated in 2F-hiSCs (dH1), 5F-hiSCs (dH1) and aSCs; and genes varying among different groups. The gene number of each group was listed next to the map. Functional enrichment terms of each group and the representative genes were shown on the right side of heat map for the upregulated gene group.

Figure 4




Figure 4. 2F-hiSCs attract endothelial cells and accumulate lipid droplets

(a) Migration assay of HUVECs incubated with the indicated conditioned media for 20 hours. HUVECs were treated with 2.5 μM Calcein-AM fluorescent dye 1 hour prior to seeding. Top, experimental diagram using the fluoroblok 24-multiwell insert plates with 8.0 μm pores. Down, fluorescent images showing cells passed through the pores.

(b) Number of HUVEC cells crossing through the transwell membrane. Each data point on the graph indicates the number of cells in one independent area. Scale bar, 300 μm. Error bars indicate standard deviations of all replicates.

(c) BODIPY staining of lipid droplets in dH1-2K7 (CTRL) and 2F-hiSCs. All cells were fixed with 4% PFA and then stained with BODIPY for lipid droplets and DAPI for nucleus.

(d) Each data point on the graph indicates the number of strong BODIPY+ cells in one image area. Scale bar, 50 μm. Error bars indicate standard deviations of all replicates.

Figure 5




Figure 5. 2F-hiSCs sustain the viability of mouse spermatogonia cells

(a) Timeline and steps of co-culturing hiSCs with mouse germ cells.

(b) Mouse spermatogonia cells plated on 2F-hiSCs or dH1-2K7. Bright-field picture was taken after 12 hours of plating. More round and healthy cells (indicated with the arrow heads) attached to hiSCs than dH1-2K7 cells. Scale bar, 10 μm .

(c) Immunofluorescent staining of germ cell marker, DAZL (green), and human-cell-specific marker, NuMA (red), in co-cultured mouse spermatogonia cells with either 2F-hiSCs or dH1-2K7, 48 hours after plating. DAPI (blue) was used to indicate the nuclei. Scale bar, 50 μm .

(d) Cell numbers with indicated markers on the co-cultured plate in (c). Each data point indicates the number of cell counted in one image area. Error bars are the standard deviations of all the counted data points.

(e) Immunofluorescent staining of DAZL (green) and KRT18 (red) in co-cultured mouse spermatogonia cells with 2F-hiSCs, 48 hours after plating. DAPI (blue) was used to indicate the nuclei. Scale bar, 50 μm .

Figure 6




Figure 6. 2F-hiSCs exhibit immunosuppressive function and protect human cells in xenotransplantations.

- (a) Schematic illustration of the WST-1 assay to measure the inhibiting effect of 2F-hiSCs on Jurkat-E6 cell proliferation. Cleavage of the tetrazolium salt WST-1 by metabolically active cells resulted in the formation of formazon. The level of formazon was directly proportional to the proliferation of the Jurkat cells.
- (b) Measurement of proliferation level in Jurkat cells treated with dH1-2K7 or 2F-hiSCs conditioned medium. X axis represent the indicated concentrations of conditioned medium. Conditioned medium from dH1-2K7 was used as a control. Values are average of triplicates, error bars indicates standard deviations, two separate experiments were conducted.
- (c) Histogram showing the production of human IL-2 in lymphocytes treated by dH1-2K7 or 2F-hiSCs conditioned medium, as measured by ELISA. Error bars indicates standard deviation of replicates from six samples.
- (d) Heat map analysis showing expression of genes involved in immunosuppression in control versus 2F-hiSCs. Genes are selected based on previous studies showing their involvement in immunosuppression of Sertoli cells.
- (e) Live imaging of luciferase-tracking assay 3 days to 10 days after transplantations. $\sim 1.3 \times 10^6$ 293FT cells were subcutaneously injected with either 2×10^5 dH1-2K7 or 2F-hiSCs cells into the indicated sites of the mouse. Cell types and locations of transplantation are indicated at left. Number in red indicates primary readings of luciferase activity, green numbers indicate fold change of luciferase activity in hiSCs + 293FT cells normalized to the controls from day3 to day10 in mouse #1.

Figure 7




Figure 7. CX43 regulates maturation of Sertoli cells

- (a) Schematic diagram showing the comparison of 2F-hiSCs cells reprogrammed from CX43 knock out fibroblasts or wild type fibroblasts. CX43KO was initially carried out in H1 hESC lines. After confirmation of CX43 KO, the hESCs were differentiated to fibroblasts (dH1 or CX43KO dH1). The fibroblasts were then reprogrammed with NR5A1 and GATA4 into 2F-hiSCs.
- (b) CX43 knockout design and the targeted sequences of the indicated hESC lines. The knockout region was located on the second exon of the CX43 gene. Three knockout cell lines were correctly targeted and mutated, one was heterozygous (06#) and the other two were homozygous (21# and 26#). Dotted lines indicate deletion mutations, red triangles indicate insertion mutations.
- (c) Immunofluorescence analysis of CX43 (red) in wild type ES cell line (01#) and knock out cell lines (26#), DAPI (blue) was used to indicate the nuclei. Scale bar, 20 μ m.
- (d) Photo bleaching assay to test the Calcien AM transport ability of fibroblasts generated from wild type ES cell line (01#) and knock out cell lines (26#).
- (e) Measurement of Calcien AM signal over time after fluorescence bleaching.
- (f) Time course experiment during 2F-hiSCs reprogramming. The AMH:EGFP+ percentage resulted from three initial fibroblasts were tested: wild type dH1, CX43 KO dH1 and CX43 KO plus CX43 overexpressed dH1.
- (g) Percentage of hiSCs(AMH:EGFP+) in WT, CX43KO and CX43KO+ CX43 overexpression from day 2 to day 25 of reprogramming.
- (h) Hierarchical clustering analysis using DEGs (FPKM value, fold change > 2) in Supplementary Fig. 7b. Genes were classified into 8 parts according to the expression pattern in CX43 KO dH1, CX43KO 2F-hiSCs, wild type dH1 and wild type 2F-hiSCs. Gene Ontology analysis of genes in part 2, 3, 7, 8 was shown on the right respectively. Other groups were shown in Supplementary Fig. 7c.
- (i) Heat map indicating expression level of immature and mature Sertoli-cell markers in WT and CX43KO 2F-hiSCs. Relative gene expression level was indicated as red (upregulated) or green (down-regulated).